NCT00511485View on ClinicalTrials.gov

Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

November 30, 2009

Conditions
Adenocarcinoma of the Lung
Interventions
DRUG

Vintafolide

Induction: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance: vintafolide 2.5 mg intravenous injection, Monday, Wednesday, and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.

DRUG

Etarfolatide

Sponsors

Lead Sponsor

Endocyte
All Listed Sponsors
lead

Endocyte

INDUSTRY

NCT00511485 - Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) | Biotech Hunter | Biotech Hunter